Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 10/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25111585 | 0.80 | DPP4 (0.48) | DPP4SMN1; SMN2TSHRHDAC2HTT | |
| SCHEMBL25910373 | 0.78 | DPP4 (0.39) | DPP4MAPTSMN1; SMN2TSHRHTT | |
| SCHEMBL3830519 | 0.78 | DPP4 (0.49) | DPP4DPP8SMN1; SMN2TSHRHDAC2 | |
| SCHEMBL3831208 | 0.76 | DPP4 (0.48) | DPP4DPP8SMN1; SMN2DPP7TSHR | |
| SCHEMBL26372132 | 0.76 | DPP4 (0.48) | DPP4DPP8SMN1; SMN2TSHRHDAC2 | |
| SCHEMBL3831210 | 0.76 | DPP4 (0.48) | DPP4DPP8SMN1; SMN2DPP7TSHR | |
| SCHEMBL3833515 | 0.76 | DPP4 (0.45) | DPP4SMN1; SMN2TSHRHDAC2 | |
| SCHEMBL3837393 | 0.76 | DPP4 (0.45) | DPP4SMN1; SMN2TSHRHDAC2 | |
| SCHEMBL3837395 | 0.76 | DPP4 (0.45) | DPP4SMN1; SMN2TSHRHDAC2 | |
| SCHEMBL14314431 | 0.76 | DPP4 (0.47) | DPP4SMN1; SMN2TSHRHDAC2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312310-A1 | Imidazothiazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20090312310-A1 | Imidazothiazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20090312310-A1 | Imidazothiazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| EP-2103619-A1 | IMIDAZOTHIAZOLE DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
| EP-2103619-A1 | IMIDAZOTHIAZOLE DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312310-A1 | Imidazothiazole derivatives | TP53, MDM2, TP53BP1 | DPP4 2929/4885MAPT 3039/4885DPP8 3304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.